Contra-indicated in patients with severe hepatic impairment (Child-Pugh C).
- TRADE NAME: Mavyret (AbbVie)
- INDICATIONS: Chronic HCV genotype 1–6 infection
- CLASS: Direct-acting antiviral, Hepatitis C virus NS3/4A protease inhibitor (glecaprevir), Hepatitis C virus NS5A inhibitor (pibrentasvir)
- HALF-LIFE: 6 hours (glecaprevir); 13 hours (pibrentasvir)
- FDA APPROVAL DATE: 08/03/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atazanavir, Atorvastatin, Carbamazepine, Cyclosporine, Darunavir, Efavirenz, Lopinavir, Lovastatin, Oral Contraceptives, Rifampin, Ritonavir, Simvastatin, St John's Wort - PREGNANCY: Insufficient evidence to inform drug-associated risk
- See adverse reactions attributed to class:
RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
